中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

39 records (took 0.02 seconds)

    LUNG CANCER-TARGETED PEPTIDES AND APPLICATIONS THEREOF
    31.
    发明申请
    LUNG CANCER-TARGETED PEPTIDES AND APPLICATIONS THEREOF 审中-公开
    肺癌癌症针灸及其应用

    公开(公告)号：WO2008100481A2

    公开(公告)日：2008-08-21

    申请号：PCT/US2008001809

    申请日：2008-02-12

    Applicant: ACADEMIA SINICA ,  UNIV NAT TAIWAN ,  WU HAN-CHUNG ,  LIN CHIN-TARNG ,  CHANG DE-KUAN

    Inventor： WU HAN-CHUNG ,  LIN CHIN-TARNG ,  CHANG DE-KUAN

    IPC: A61K9/127 ,  A61K47/48 ,  C07K7/04

    CPC classification number: G01N33/57423 ,  A61K9/1271 ,  A61K47/62 ,  A61K47/6911 ,  A61K51/1234 ,  C07K7/08

    Abstract: The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target lung cancer and were identified by phage display. Targeting phage PC5-2 and synthetic peptide SP5-2 were both able to recognize human pulmonary tumor specimens from lung cancer patients. In SCID mice bearing NSCLC xenografts, the targeting phage was able to target tumor masses specifically. When the peptide was coupled to liposomes containing the anti-cancer drugs vinorelbine or doxorubicin, the efficacy of these drugs against human lung cancer xenografts was improved, the survival rate increased, and the drug toxicity was reduced.

    Abstract translation: 本发明提供用于包括诊断和治疗在内的应用的核酸，肽和抗体。 这些肽靶向肺癌，并通过噬菌体展示鉴定。 靶向噬菌体PC5-2和合成肽SP5-2都能够识别来自肺癌患者的人肺肿瘤标本。 在携带NSCLC异种移植物的SCID小鼠中，靶向噬菌体能够特异性地靶向肿瘤块。 当肽与含有抗癌药物长春瑞滨或多柔比星的脂质体偶联时，这些药物对人肺癌异种移植物的功效得到改善，存活率提高，药物毒性降低。

    PEPTIDES SPECIFIC FOR HEPATOCELLULAR CARCINOMA CELLS AND APPLICATIONS THEREOF
    34.
    发明申请
    PEPTIDES SPECIFIC FOR HEPATOCELLULAR CARCINOMA CELLS AND APPLICATIONS THEREOF 审中-公开
    肝细胞癌细胞特异性蛋白及其应用

    公开(公告)号：WO2009067520A3

    公开(公告)日：2009-09-03

    申请号：PCT/US2008084043

    申请日：2008-11-19

    Applicant: ACADEMIA SINICA ,  WU HAN-CHUNG ,  LIN CHIN-TARNG ,  LO ALBERT

    Inventor： WU HAN-CHUNG ,  LIN CHIN-TARNG ,  LO ALBERT

    IPC: C07K7/08 ,  A61K9/127 ,  A61P35/00 ,  C07K16/00 ,  G01N33/53

    CPC classification number: G01N33/57438 ,  A61K38/00 ,  C07K7/08

    Abstract: Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. Novel treatment strategies derived from increased knowledge of molecular oncology are constantly being developed to cure this disease. Here, we used phage display to identify novel peptides, including (SP94), which binds specifically to HCC cells. In vitro, the phage clone PC94 binds to HCC cell lines. In vivo, PC94 homed specifically to tumor tissues but not to normal visceral organs in SCID mice bearing human HCC xenografts. The homing ability could be competitively inhibited by synthetic peptide, SP94. PC94 localized to tumor tissues but could not be detected in SP94-competed tumor tissues or in normal organs. In addition, PC94 recognized the tumor tissue but not non-tumor tissue in surgical specimens from HCC patients, with a positive rate of 61.3% (19/31). With the conjugation of SP94 and liposomal doxorubicin, a targeted drug delivery system enhanced the therapeutic efficacy against HCC xenografts through enhanced tumor apoptosis and decreased tumor angiogenesis. Our results indicate that SP94 can improve the systemic treatment of patients with advanced HCC.

    Abstract translation: 肝细胞癌（HCC）是全球第四大癌症死亡原因。 不断开发从增加分子肿瘤学知识得出的新型治疗策略来治愈这种疾病。 在这里，我们使用噬菌体展示来鉴定新型肽，包括特异性结合HCC细胞的（SP94）。 在体外，噬菌体克隆PC94结合HCC细胞系。 在体内，PC94特异性地归巢于肿瘤组织，而不是携带人类HCC异种移植物的SCID小鼠中的正常内脏器官。 归巢能力可以被合成肽SP94竞争性抑制。 PC94定位于肿瘤组织，但在SP94竞争的肿瘤组织或正常器官中不能检测到。 此外，PC94在HCC患者手术标本中识别肿瘤组织，但不识别非肿瘤组织，阳性率为61.3％（19/31）。 通过SP94和脂质体多柔比星的缀合，靶向药物递送系统通过增强肿瘤细胞凋亡和减少肿瘤血管生成来增强对HCC异种移植物的治疗效果。 我们的研究结果表明，SP94可以改善晚期HCC患者的全身治疗。

    THE CAPTURE, PURIFICATION AND RELEASE OF BIOLOGICAL SUBSTANCE USING A SURFACE COATING
    38.
    发明公开
    THE CAPTURE, PURIFICATION AND RELEASE OF BIOLOGICAL SUBSTANCE USING A SURFACE COATING 审中-公开
    收购，护理和生物物质ANAHND表面涂层释放

    公开(公告)号：EP2726870A4

    公开(公告)日：2015-03-11

    申请号：EP12805303

    申请日：2012-06-28

    Applicant: ACADEMIA SINICA

    Inventor： CHANG YING-CHIH ,  WU HAN-CHUNG ,  TSENG PO-YUAN

    IPC: G01N33/53 ,  C07K17/14

    CPC classification number: G01N33/54386 ,  C07K16/30 ,  C07K17/14 ,  G01N1/405 ,  G01N33/54393 ,  G01N33/57492

    Abstract: This invention relates to a surface coating for capture circulating rare cells, comprising a nonfouling composition to prevent the binding of non-specific cells and adsorption of serum components; a bioactive composition for binding the biological substance, such as circulating tumor cells; with or without a linker composition that binds the nonfouling and bioactive compositions. The invention also provide a surface coating for capture and purification of a biological substance, comprising a releasable composition to release the non-specific cells and other serum components; a bioactive composition for binding the biological substance, such as circulating tumor cells; with or without a linker composition that binds the releasable and bioactive compositions. The present invention also discloses a novel microfluidic chip, with specific patterned microstructures to create a flow disturbance and increase the capture rate of the biological substance.

    Abstract translation: 本发明涉及一种用于捕获循环稀有细胞，其包含不结垢组合物，以防止非特异性细胞和血清成分的吸附的结合的表面涂层; 用于结合的生物物质，颜色的生物活性组合物：如循环肿瘤细胞; 具有或不具有左组合物做了结合不结垢和生物活性的组合物。 因此，本发明提供用于生物物质的捕获和纯化的表面涂层，其包括可释放的组合物，以释放非特异性细胞和其它血清组分; 用于结合的生物物质，颜色的生物活性组合物：如循环肿瘤细胞; 具有或不具有左组合物确实结合释放的生物活性和组合物。 因此，本发明光盘松一新颖微流体芯片，与特定的微结构图案化以产生一个流动扰动并增加生物物质的捕获率。

Patent Agency Ranking